Cargando…
Novel Approaches for the Treatment of Alzheimer’s and Parkinson’s Disease
Neurodegenerative disorders affect around one billion people worldwide. They can arise from a combination of genomic, epigenomic, metabolic, and environmental factors. Aging is the leading risk factor for most chronic illnesses of old age, including Alzheimer’s and Parkinson’s diseases. A progressiv...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6386829/ https://www.ncbi.nlm.nih.gov/pubmed/30743990 http://dx.doi.org/10.3390/ijms20030719 |
_version_ | 1783397431734435840 |
---|---|
author | Van Bulck, Michiel Sierra-Magro, Ana Alarcon-Gil, Jesus Perez-Castillo, Ana Morales-Garcia, Jose A. |
author_facet | Van Bulck, Michiel Sierra-Magro, Ana Alarcon-Gil, Jesus Perez-Castillo, Ana Morales-Garcia, Jose A. |
author_sort | Van Bulck, Michiel |
collection | PubMed |
description | Neurodegenerative disorders affect around one billion people worldwide. They can arise from a combination of genomic, epigenomic, metabolic, and environmental factors. Aging is the leading risk factor for most chronic illnesses of old age, including Alzheimer’s and Parkinson’s diseases. A progressive neurodegenerative process and neuroinflammation occur, and no current therapies can prevent, slow, or halt disease progression. To date, no novel disease-modifying therapies have been shown to provide significant benefit for patients who suffer from these devastating disorders. Therefore, early diagnosis and the discovery of new targets and novel therapies are of upmost importance. Neurodegenerative diseases, like in other age-related disorders, the progression of pathology begins many years before the onset of symptoms. Many efforts in this field have led to the conclusion that exits some similar events among these diseases that can explain why the aging brain is so vulnerable to suffer neurodegenerative diseases. This article reviews the current knowledge about these diseases by summarizing the most common features of major neurodegenerative disorders, their causes and consequences, and the proposed novel therapeutic approaches. |
format | Online Article Text |
id | pubmed-6386829 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-63868292019-02-27 Novel Approaches for the Treatment of Alzheimer’s and Parkinson’s Disease Van Bulck, Michiel Sierra-Magro, Ana Alarcon-Gil, Jesus Perez-Castillo, Ana Morales-Garcia, Jose A. Int J Mol Sci Review Neurodegenerative disorders affect around one billion people worldwide. They can arise from a combination of genomic, epigenomic, metabolic, and environmental factors. Aging is the leading risk factor for most chronic illnesses of old age, including Alzheimer’s and Parkinson’s diseases. A progressive neurodegenerative process and neuroinflammation occur, and no current therapies can prevent, slow, or halt disease progression. To date, no novel disease-modifying therapies have been shown to provide significant benefit for patients who suffer from these devastating disorders. Therefore, early diagnosis and the discovery of new targets and novel therapies are of upmost importance. Neurodegenerative diseases, like in other age-related disorders, the progression of pathology begins many years before the onset of symptoms. Many efforts in this field have led to the conclusion that exits some similar events among these diseases that can explain why the aging brain is so vulnerable to suffer neurodegenerative diseases. This article reviews the current knowledge about these diseases by summarizing the most common features of major neurodegenerative disorders, their causes and consequences, and the proposed novel therapeutic approaches. MDPI 2019-02-08 /pmc/articles/PMC6386829/ /pubmed/30743990 http://dx.doi.org/10.3390/ijms20030719 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Van Bulck, Michiel Sierra-Magro, Ana Alarcon-Gil, Jesus Perez-Castillo, Ana Morales-Garcia, Jose A. Novel Approaches for the Treatment of Alzheimer’s and Parkinson’s Disease |
title | Novel Approaches for the Treatment of Alzheimer’s and Parkinson’s Disease |
title_full | Novel Approaches for the Treatment of Alzheimer’s and Parkinson’s Disease |
title_fullStr | Novel Approaches for the Treatment of Alzheimer’s and Parkinson’s Disease |
title_full_unstemmed | Novel Approaches for the Treatment of Alzheimer’s and Parkinson’s Disease |
title_short | Novel Approaches for the Treatment of Alzheimer’s and Parkinson’s Disease |
title_sort | novel approaches for the treatment of alzheimer’s and parkinson’s disease |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6386829/ https://www.ncbi.nlm.nih.gov/pubmed/30743990 http://dx.doi.org/10.3390/ijms20030719 |
work_keys_str_mv | AT vanbulckmichiel novelapproachesforthetreatmentofalzheimersandparkinsonsdisease AT sierramagroana novelapproachesforthetreatmentofalzheimersandparkinsonsdisease AT alarcongiljesus novelapproachesforthetreatmentofalzheimersandparkinsonsdisease AT perezcastilloana novelapproachesforthetreatmentofalzheimersandparkinsonsdisease AT moralesgarciajosea novelapproachesforthetreatmentofalzheimersandparkinsonsdisease |